Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 5 studies | 19% ± 3% | |
epithelial cell | 4 studies | 32% ± 10% | |
B cell | 3 studies | 20% ± 5% | |
CD16-positive, CD56-dim natural killer cell, human | 3 studies | 18% ± 1% | |
innate lymphoid cell | 3 studies | 20% ± 3% | |
abnormal cell | 3 studies | 16% ± 1% | |
goblet cell | 3 studies | 19% ± 2% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 3 studies | 21% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 4699.96 | 1445 / 1445 | 100% | 61.40 | 183 / 183 |
liver | 100% | 2621.09 | 226 / 226 | 100% | 46.93 | 406 / 406 |
ovary | 100% | 5826.62 | 180 / 180 | 100% | 79.81 | 430 / 430 |
pancreas | 100% | 2642.99 | 328 / 328 | 100% | 71.76 | 178 / 178 |
prostate | 100% | 5854.10 | 245 / 245 | 100% | 90.94 | 502 / 502 |
skin | 100% | 5065.59 | 1809 / 1809 | 100% | 78.52 | 472 / 472 |
stomach | 100% | 3753.10 | 359 / 359 | 100% | 67.75 | 286 / 286 |
thymus | 100% | 5844.49 | 653 / 653 | 100% | 98.81 | 605 / 605 |
uterus | 100% | 5897.23 | 170 / 170 | 100% | 78.80 | 459 / 459 |
brain | 100% | 5755.82 | 2641 / 2642 | 100% | 95.67 | 705 / 705 |
lung | 100% | 5207.75 | 578 / 578 | 100% | 66.99 | 1154 / 1155 |
kidney | 100% | 4699.67 | 89 / 89 | 100% | 64.90 | 900 / 901 |
intestine | 100% | 5494.15 | 966 / 966 | 100% | 69.85 | 526 / 527 |
bladder | 100% | 5073.76 | 21 / 21 | 100% | 68.46 | 502 / 504 |
adrenal gland | 100% | 5321.65 | 258 / 258 | 100% | 77.17 | 229 / 230 |
breast | 100% | 4840.64 | 459 / 459 | 100% | 75.67 | 1113 / 1118 |
adipose | 100% | 4741.41 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 5032.92 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 69.67 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 127.42 | 29 / 29 |
spleen | 100% | 7792.46 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 73.77 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 38.53 | 1 / 1 |
peripheral blood | 100% | 6062.07 | 928 / 929 | 0% | 0 | 0 / 0 |
muscle | 100% | 2880.32 | 801 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 2404.35 | 851 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0014033 | Biological process | neural crest cell differentiation |
GO_0032480 | Biological process | negative regulation of type I interferon production |
GO_0071108 | Biological process | protein K48-linked deubiquitination |
GO_0070536 | Biological process | protein K63-linked deubiquitination |
GO_1904263 | Biological process | positive regulation of TORC1 signaling |
GO_0006508 | Biological process | proteolysis |
GO_0090090 | Biological process | negative regulation of canonical Wnt signaling pathway |
GO_0032496 | Biological process | response to lipopolysaccharide |
GO_1904515 | Biological process | positive regulation of TORC2 signaling |
GO_0016579 | Biological process | protein deubiquitination |
GO_0005829 | Cellular component | cytosol |
GO_0005634 | Cellular component | nucleus |
GO_1990380 | Molecular function | K48-linked deubiquitinase activity |
GO_0101005 | Molecular function | deubiquitinase activity |
GO_0004843 | Molecular function | cysteine-type deubiquitinase activity |
GO_0061578 | Molecular function | K63-linked deubiquitinase activity |
Gene name | OTUD5 |
Protein name | ubiquitinyl hydrolase 1 (EC 3.4.19.12) (Deubiquitinating enzyme A) OTU domain-containing protein 5 (EC 3.4.19.12) (Deubiquitinating enzyme A) (DUBA) |
Synonyms | |
Description | FUNCTION: Deubiquitinating enzyme that functions as a negative regulator of the innate immune system . Has peptidase activity towards 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains . Can also cleave 'Lys-11'-linked ubiquitin chains (in vitro) . Acts via TRAF3 deubiquitination and subsequent suppression of type I interferon (IFN) production . Controls neuroectodermal differentiation through cleaving 'Lys-48'-linked ubiquitin chains to counteract degradation of select chromatin regulators such as ARID1A, HDAC2 and HCF1 . Acts as a positive regulator of mTORC1 and mTORC2 signaling following phosphorylation by MTOR: acts by mediating deubiquitination of BTRC, leading to its stability . . |
Accessions | ENST00000710076.1 [Q96G74-4] ENST00000376488.8 [Q96G74-5] Q96G74 ENST00000428668.2 [Q96G74-4] ENST00000710073.1 [Q96G74-5] ENST00000396743.7 [Q96G74-5] ENST00000156084.8 [Q96G74-1] ENST00000455452.5 H7BZQ3 ENST00000710072.1 [Q96G74-5] ENST00000710075.1 [Q96G74-1] |